Affiliation:
1. Novartis Pharmaceuticals Corporation, San Carlos, CA 94070, USA.
2. Novartis Pharmaceuticals Corporation, San Carlos, CA 94070, USA
Abstract
Spray–dried PulmoSphere™ formulations comprise phospholipid-based small, porous particles. Drug(s) may be incorporated in or with PulmoSphere formulations in three formats: solution-, suspension-, and carrier-based systems. The multiple formats may be administered to the respiratory tract with multiple delivery systems, including portable inhalers (pressurized, metered-dose inhaler and dry-powder inhaler), nebulizers, and via liquid dose instillation in conjunction with partial liquid ventilation. The PulmoSphere platform (particles, formats, delivery systems) enables pulmonary delivery of a broad range of drugs independent of their physicochemical properties and lung dose. The engineered particles provide significant improvements in lung targeting and dose consistency, relative to current marketed inhalers.
Reference88 articles.
1. Clinical trials. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non-CF BE)(RESPIRE 1).www.clinicaltrials.gov/ct2/show/NCT01764841
2. Clinical trials. Efficacy and safety of PT003, PT005, and PT001 in subjects with moderate to severe COPD (PINNACLE 1).www.clinicaltrials.gov/ct2/show/NCT01854645
3. Pharmaceutical Particle Engineering via Spray Drying
4. The use of modeling in spray drying of emulsions and suspensions accelerates formulation and process development
Cited by
103 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献